These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28301705)

  • 1. Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations.
    Hey SP; Kesselheim AS
    Hastings Cent Rep; 2017 Mar; 47(2):16-20. PubMed ID: 28301705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the GAIN Act a turning point in new antibiotic discovery?
    Brown ED
    Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More regulation of industry-supported biomedical research: are we asking the right questions?
    Fry-Revere S; Malmstrom DB
    J Law Med Ethics; 2009; 37(3):420-30, 395. PubMed ID: 19723253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The roles of patents and research and development incentives in biopharmaceutical innovation.
    Grabowski HG; DiMasi JA; Long G
    Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?
    Talbot GH; Jezek A; Murray BE; Jones RN; Ebright RH; Nau GJ; Rodvold KA; Newland JG; Boucher HW;
    Clin Infect Dis; 2019 Jun; 69(1):1-11. PubMed ID: 30715222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
    Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
    Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 21st Century Cures Act: pharmacoeconomic boon or bane?
    Mendoza RL
    J Med Econ; 2017 Apr; 20(4):315-317. PubMed ID: 28092219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic resistance.
    Rambhia KJ; Gronvall GK
    Biosecur Bioterror; 2009 Dec; 7(4):371-7. PubMed ID: 20028245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. History of Antibiotics Research.
    Mohr KI
    Curr Top Microbiol Immunol; 2016; 398():237-272. PubMed ID: 27738915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outlook: the profit problem in antibiotic R&D.
    Nathan C; Goldberg FM
    Nat Rev Drug Discov; 2005 Nov; 4(11):887-91. PubMed ID: 16247440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections.
    Hwang TJ; Kesselheim AS
    Am J Law Med; 2016 May; 42(2-3):429-450. PubMed ID: 29086648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.